So Miyoshi, PhD

Head of Clinical Pharmacology
Pfizer R&D Japan

Dr. So Miyoshi has been Head of Clinical Pharmacology at Pfizer R&D Japan since 2015. He has more than 20 years of experience in application of quantitative clinical pharmacology and pharmacometrics for clinical development and new drug application work not only for Japan but also for US, Europe, China and Korea as Global Clinical Pharmacology Lead and Pharmacometrician. He received his PhD in Pharmaceutical Science from Kyushu University in 2008. He has chaired and organized sessions at many domestic and intranational conferences including the Population Approach Group in Japan, the Japanese Society of Clinical Pharmacology and Therapeutics, and Drug Information Association (DIA). He is Community Lead of Clinical Pharmacology, which was establised in December 2021, in DIA Japan. Dr. Miyoshi served as Leader of Clinical Pharmacology Task Force in the Japan Pharmaceutical Manufacturers Association (JPMA) in 2015-2020. He is Topic Leader of ICH Expert WG for Drug-Drug Interaction (M12) as JPMA representative. Dr. So Miyoshi currently serves on the Board of Directors of the International Society of Pharmacometrics as Asia representative.

Disclosure information not submitted.

Presentation(s):

• DDI Risk Assessment: Approaching Global Convergence and Understanding Emerging Innovation

  Monday, April 25, 2022
  8:00 AM – 1:30 PM ET